Dechra Pharmaceuticals PLC is an England-based business involved in the development and marketing of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
Dechra Pharmaceuticals PLC is an England-based business involved in the development and marketing of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
Dechra Pharmaceuticals plc (LON:DPH) has announced that after 12 years’ service with Dechra, Tony Griffin will step...
The Board of The Baillie Gifford Japan Trust PLC (LON:BGFD) has announced the appointment of Patricia Lewis...
Dechra Pharmaceuticals PLC (LON:DPH) has issued today the following unaudited trading update in respect of the financial...
Dechra Pharmaceuticals plc (LON:DPH) has issued the following statement prior to the Annual General Meeting (AGM) which...
Dechra Pharmaceuticals PLC (LON:CPH) has issued its audited preliminary results for the year ended 30 June 2022.
...
Dechra Pharmaceuticals plc (LON:DPH) has announced it has acquired Med-Pharmex, Inc. Med-Pharmex is a leading veterinary pharmaceutical...
Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.